5-Amino-1MQ: an enzyme inhibitor with a coherent mechanism and no human data

A small molecule with a specific, well-described target and a preclinical story that hangs together. What it does not have is a single published human trial, which is worth holding on to while reading anything that sells it.

What NNMT does, and what blocking it is meant to achieve

Established clinical use Nicotinamide N-methyltransferase takes nicotinamide — the salvage-pathway precursor cells use to regenerate NAD+ — and methylates it into a form destined for excretion. High NNMT activity therefore diverts nicotinamide away from NAD+ regeneration and consumes methyl groups doing it. NNMT is expressed strongly in adipose tissue and liver, and its expression rises in obesity.

Animal-only or theoretical 5-Amino-1MQ is a small-molecule inhibitor of that enzyme. The proposed consequence is straightforward: block the diversion, intracellular NAD+ rises in the tissues where NNMT is most active, sirtuin signalling increases, and fat cells shift toward oxidation. Rodent work has reported reduced fat mass without reduced food intake, which is the finding that generated the interest.

The NMN and NR page covers the other approach to the same target: supplying more precursor rather than stopping its removal. The two are mechanistically distinct routes to the same intracellular quantity, and only one of them has human data showing the quantity actually moves.

How thin the human evidence is

Animal-only or theoretical There is no published randomised controlled trial of 5-Amino-1MQ in people. No published pharmacokinetics in people either — the app records no half-life or time to peak, which is why the fact box has no pharmacokinetic rows, and the dosing row it does hold is convention rather than a finding. The app’s own drawbacks list says research is primarily preclinical and dosing is not standardised, which is the accurate summary.

Two specific unknowns follow from the mechanism rather than from the absence of trials. NNMT inhibition affects methyl-group metabolism, which touches a great deal more than fat cells — DNA methylation among it — and nobody has characterised what sustained inhibition does to that in a person. And NNMT expression varies substantially between tissues and individuals, so the effect of inhibiting it is unlikely to be uniform.

None of that makes it dangerous. It makes it unstudied, which is a different and more accurate word, and it is the same position pentadeca arginate occupies on this site.

What to do with it

There is no approved product and it is sold as a compounded or research-supply oral preparation. Identity, purity and content rest entirely with whoever made it, and this site names no pharmacy, vendor or testing service.

The app’s monitoring list is body composition, glucose, insulin and HbA1c, which is the sensible set for the proposed mechanism and is the only assessment available — nothing measures NNMT activity or intracellular NAD+ outside a research setting. The HbA1c page covers why the two glucose markers can disagree.

The reasonable position is interest without confidence: a specific target, a coherent preclinical case, and a complete absence of the evidence that would tell you whether any of it happens in a person. Anyone using it should treat their own record as the entire dataset, and anyone with a metabolic condition should be raising it with the clinician managing it.

The dosing rows the app records

Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for 5-Amino-1MQ, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Hematocrit on testosterone therapy
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app’s own entry, and it is refreshingly blunt: the first three items say preclinical, unstudied and unstandardised, which is the whole picture.

• Limited human clinical data
• Research primarily preclinical
• Long-term safety not established
• Requires compounding pharmacy
• Dosing not standardized
• Potential interactions with NAD+ pathways

Questions people actually ask

Is there any human data?

No published randomised trial, and no published human pharmacokinetics. The evidence is preclinical, and the dosing in circulation is convention rather than a finding.

How is it different from taking NMN?

Opposite ends of the same pathway. NMN supplies more precursor; this blocks the enzyme that removes it. NMN has human data showing blood NAD+ rises; this has none showing anything happens in a person.

Why does methyl metabolism come up?

Because the enzyme it inhibits consumes methyl groups. Blocking it does not only affect fat cells — it changes the availability of methyl groups for other processes, DNA methylation included, and nobody has characterised that under sustained inhibition.

Why is there no half-life in the fact box?

Because none has been published, so the app holds none. Any duration figure quoted for it elsewhere is not from a characterisation study.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.